CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape

CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.

Tumor escape and recurrence are major impediments for successful immunotherapy. It is well-documented that the emergence of Ag-loss variants, as well as regulatory mechanisms suppressing T cell function, have been linked to inadequate antitumor activity. However, little is known regarding the role of Fas-mediated cytotoxicity by tumor-specific CD8(+) CTL in causing immune evasion of Fas resista...

Adoptive Immunotherapy and Enhances CTL Lytic Activity and CTL Irradiation of Tumor Cells Up-Regulates Fas

Cells in Adoptive Tumor Immunotherapy

Recent publications from this laboratory (1, 2) have shown that it is possible to cause the regression of established immunogenic murine tumors by the passive transfer of tumor-sensitized T cells from immunized donors, provided the tumor-bearing recipients have been made T cell-deficient by thymectomy and irradiation. The need for T cell-deficient tumor-bearing recipients to demonstrate success...

Tumor Regression After Adoptive Transfer

Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.

Adoptive immunotherapy using CTL has provided some clinical benefit to patients with metastatic melanoma. Use of cloned CTL of known specificity might improve clinical effect, but technical difficulties have limited exploration of this possibility. We have used fluorescence-driven cell sorting to clone tumor-specific CTL after staining with tetrameric MHC class I/peptide complexes. CTL specific...